2026 Q3
Category: dates
Third Quarter 2026 Financial Results
First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
BT-001 rectacl cancer
PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery
J. Foloppe et al. SITC 2026 – Abstract available on the SITC website – Download the Abstract– Download the Poster
Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
SITC 2026 Abstract
Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties
A. Agaoua et al. frontiers in Bioengineering and Biotechnology – Article available on the frontiers website – Download the Article
Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
SITC 2026
Transgene To Participate in Investor Access
Investor Access
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
2026 Half Year results
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
ProBioGen